Prognostic Value of CD109+ Circulating Endothelial Cells in Recurrent Glioblastomas Treated with Bevacizumab and Irinotecan

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Cuppini, Lucia ^a   Calleri, Angelica ^b   Bruzzone, Maria Grazia ^a   Prodi, Elena ^a   Anghileri, Elena ^a   Pellegatta, Serena ^a   Mancuso, Patrizia ^b   Porrati, Paola ^a   Di Stefano, Anna Luisa ^a,c   Ceroni, Mauro ^c   Bertolini, Francesco ^b   Finocchiaro, Gaetano ^a   Eoli, Marica ^a  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CD109 ANTIGEN; FOTEMUSTINE; IRINOTECAN; TEMOZOLOMIDE; TUMOR MARKER; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STEM CELL; CANCER SURVIVAL; CEREBRAL SINUS THROMBOSIS; CIRCULATING ENDOTHELIAL CELL; CIRCULATING ENDOTHELIAL PROGENITOR CELL; CONTROLLED STUDY; DISTANT METASTASIS; ENDOTHELIUM CELL; FEMALE; FLOW CYTOMETRY; GLIOBLASTOMA; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; POSTOPERATIVE INFECTION; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; SURVIVAL TIME; TUMOR BLEEDING;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DISEASE PROGRESSION; ENDOTHELIAL CELLS; FEMALE; GLIOBLASTOMA; GPI-LINKED PROTEINS; HUMANS; IMMUNOPHENOTYPING; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84884194253     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074345     Document Type: Article

References (51)

1. Iwamoto FM, Fine HA, (2010) Bevacizumab for malignant gliomas. Arch Neurol 67: 285-288. doi:10.1001/archneurol.2010.11. PubMed: 20212225.
2. Jubb AM, Harris AL, (2010) Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol 11: 1172-1183. doi:10.1016/S1470-2045(10)70232-1. PubMed: 21126687.
3. Bertolini F, Shaked Y, Mancuso P, Kerbel RS, (2006) The multifaceted circulating endothelial cell in cancer: Towards marker and target identification. Nat Rev Cancer 6: 835-845. doi:10.1038/nrc1971. PubMed: 17036040.
4. Bertolini F, Mancuso P, Shaked Y, (2011) Circulating endothelial cells as biomarkers for patients receiving bevacizumab. Lancet Oncol 12: 217-218. doi:10.1016/S1470-2045(11)70050-X. PubMed: 21376289.
5. Calleri A, Bono A, Bagnardi V, Quarna J, Mancuso P, et al. (2009) Predictive potential of angiogenic growth factors and circulating endothelial cells in breast cancer patients receiving metronomic chemotherapy plus bevacizumab. Clin Cancer Res 15: 7652-7657. doi:10.1158/1078-0432.CCR-09-1493. PubMed: 19996223.
6. Plate KH, Breier G, Weich HA, Risau W, (1992) Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359: 845-848. doi:10.1038/359845a0. PubMed: 1279432.
7. Li B, Sharpe EE, Maupin AB, Teleron AA, Pyle AL, et al. (2006) VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization. FASEB J 20: 1495-1497. doi:10.1096/fj.05-5137fje. PubMed: 16754748.
8. Asahara T, Takahashi T, Masuda H, Kalka C, Chen D, et al. (1999) VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 18: 3964-3972. doi:10.1093/emboj/18.14.3964. PubMed: 10406801.
9. Rafat N, Beck GC, Schulte J, Tuettenberg J, Vajkoczy P, (2010) Circulating endothelial progenitor cells in malignant gliomas. J Neurosurg 112: 43-49. doi:10.3171/2009.5.JNS081074. PubMed: 19522573.
10. Song S, Ewald AJ, Stallcup W, Werb Z, Bergers G, (2005) PDGFRbeta+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat Cell Biol 7: 870-879.
11. Bababeygy SR, Cheshier SH, Hou LC, Higgins DM, Weissman IL, et al. (2008) Hematopoietic stem cell-derived pericytic cells in brain tumor angio-architecture. Stem Cells Dev 17: 11-18. doi:10.1089/scd.2007.0117. PubMed: 18240955.
12. Franco M, Roswall P, Cortez E, Hanahan D, Pietras K, (2011) Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and bcl-w expression. Blood 118: 2906-2917. doi:10.1182/blood-2011-01-331694. PubMed: 21778339.
13. Cao Y, Zhang ZL, Zhou M, Elson P, Rini B, et al. (2012) Pericyte coverage of differentiated vessels inside tumor vasculature is an independent unfavorable prognostic factor for patients with clear cell renal cell carcinoma. Cancer, 119: 313-24. PubMed: 22811049.
14. Ronzoni M, Manzoni M, Mariucci S, Loupakis F, Brugnatelli S, et al. (2010) Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to bevacizumab-based first-line treatment in advanced colorectal cancer patients. Ann Oncol 21: 2382-2389. doi:10.1093/annonc/mdq261. PubMed: 20497963.
15. Simkens LH, Tol J, Terstappen LW, Teerenstra S, Punt CJ, et al. (2010) The predictive and prognostic value of circulating endothelial cells in advanced colorectal cancer patients receiving first-line chemotherapy and bevacizumab. Ann Oncol 21: 2447-2448. doi:10.1093/annonc/mdq640. PubMed: 21030382.
16. Murakami H, Ogata Y, Akagi Y, Ishibashi N, Shirouzu K, (2011) Circulating endothelial progenitor cells in metronomic chemotherapy using irinotecan and/or bevacizumab for colon carcinoma: Study of their clinical significance. Exp Ther Med 2: 595-600. PubMed: 22977546.
17. Matsusaka S, Suenaga M, Mishima Y, Takagi K, Terui Y, et al. (2011) Circulating endothelial cells predict for response to bevacizumab-based chemotherapy in metastatic colorectal cancer. Cancer Chemother Pharmacol 68: 763-768. doi:10.1007/s00280-010-1543-2. PubMed: 21170650.
18. Malka D, Boige V, Jacques N, Vimond N, Adenis A, et al. (2012) Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab. Ann Oncol 23: 919-927. doi:10.1093/annonc/mdr365. PubMed: 21825101.
19. Bidard FC, Mathiot C, Degeorges A, Etienne-Grimaldi MC, Delva R, et al. (2010) Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy. Ann Oncol 21: 1765-1771. doi:10.1093/annonc/mdq052. PubMed: 20233745.
20. Fleitas T, Martínez-Sales V, Vila V, Reganon E, Mesado D, et al. (2012) Circulating endothelial cells and microparticles as prognostic markers in advanced non-small cell lung cancer. PLOS ONE 7: e47365. doi:10.1371/journal.pone.0047365. PubMed: 23077602.
21. Seaman S, Stevens J, Yang MY, Logsdon D, Graff-Cherry C, et al. (2007) Genes that distinguish physiological and pathological angiogenesis. Cancer Cell 11: 539-554. doi:10.1016/j.ccr.2007.04.017. PubMed: 17560335.
22. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996. doi:10.1056/NEJMoa043330. PubMed: 15758009.
23. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Dowell JM, Reardon DA, et al. (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13: 1253-1259. doi:10.1158/1078-0432.CCR-06-2309. PubMed: 17317837.
24. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, et al. (2010) Updated response assessment criteria for high-grade gliomas: Response assessment in neuro-oncology working group. J Clin Oncol 28: 1963-1972. doi:10.1200/JCO.2009.26.3541. PubMed: 20231676.
25. Chamberlain MC, (2011) Radiographic patterns of relapse in glioblastoma. J Neuro Oncol 101: 319-323. doi:10.1007/s11060-010-0251-4. PubMed: 21052776.
26. Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, et al. (2008) Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence. Neurology 70: 779-787. doi:10.1212/01.wnl.0000304121.57857.38. PubMed: 18316689.
27. Mancuso P, Antoniotti P, Quarna J, Calleri A, Rabascio C, et al. (2009) Validation of a standardized method for enumerating circulating endothelial cells and progenitors: Flow cytometry and molecular and ultrastructural analyses. Clin Cancer Res 15: 267-273. doi:10.1158/1078-0432.CCR-08-0432. PubMed: 19118054.
28. Mead LE, Prater D, Yoder MC, Ingram DA, (2008) Isolation and characterization of endothelial progenitor cells from human blood. Curr Protoc Stem Cell Biol Chapter 2Unit 2C1. PubMed: 18770637.
29. Case J, Mead LE, Bessler WK, Prater D, White HA, et al. (2007) Human CD34+AC133+VEGFR-2+ cells are not endothelial progenitor cells but distinct, primitive hematopoietic progenitors. Exp Hematol 35: 1109-1118. doi:10.1016/j.exphem.2007.04.002. PubMed: 17588480.
30. Estes ML, Mund JA, Mead LE, Prater DN, Cai S, et al. (2010) Application of polychromatic flow cytometry to identify novel subsets of circulating cells with angiogenic potential. Cytometry A 77: 831-839. PubMed: 20803735.
31. Mancuso P, Martin-Padura I, Calleri A, Marighetti P, Quarna J, et al. (2011) Circulating perivascular progenitors: A target of PDGFR inhibition. Int J Cancer 129: 1344-1350. doi:10.1002/ijc.25816. PubMed: 21128230.
32. Perry JR, Bélanger K, Mason WP, Fulton D, Kavan P, et al. (2010) Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol 28: 2051-2057. doi:10.1200/JCO.2009.26.5520. PubMed: 20308655.
33. Beerepoot LV, Mehra N, Vermaat JS, Zonnenberg BA, Gebbink MF, et al. (2004) Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients. Ann Oncol 15: 139-145. doi:10.1093/annonc/mdh017. PubMed: 14679134.
34. Lin M, Sutherland DR, Horsfall W, Totty N, Yeo E, et al. (2002) Cell surface antigen CD109 is a novel member of the alpha(2) macroglobulin/C3, C4, C5 family of thioester-containing proteins. Blood 99: 1683-1691. doi:10.1182/blood.V99.5.1683. PubMed: 11861284.
35. Hashimoto M, Ichihara M, Watanabe T, Kawai K, Koshikawa K, et al. (2004) Expression of CD109 in human cancer. Oncogene 23: 3716-3720. doi:10.1038/sj.onc.1207418. PubMed: 15116102.
36. Greenberg JI, Shields DJ, Barillas SG, Acevedo LM, Murphy E, et al. (2008) A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature 456: 809-813. doi:10.1038/nature07424. PubMed: 18997771.
37. Weisshardt P, Trarbach T, Dürig J, Paul A, Reis H, et al. (2012) Tumor vessel stabilization and remodeling by anti-angiogenic therapy with bevacizumab. Histochem Cell Biol 137: 391-401. doi:10.1007/s00418-011-0898-8. PubMed: 22193946.
38. Keunen O, Johansson M, Oudin A, Sanzey M, Rahim SA, et al. (2011) Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci U S A 108: 3749-3754. doi:10.1073/pnas.1014480108. PubMed: 21321221.
39. Lu KV, Chang JP, Parachoniak CA, Pandika MM, Aghi MK, et al. (2012) VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell 22: 21-35. doi:10.1016/j.ccr.2012.05.037. PubMed: 22789536.
40. Wong ET, Gautam S, Malchow C, Lun M, Pan E, et al. (2011) Bevacizumab for recurrent glioblastoma multiforme: A meta-analysis. J Natl Compr Canc Netw 9: 403-407. PubMed: 21464145.
41. Gil MJ, de Las Peñas R, Reynés G, Balañá C, Peréz-Segura P, et al. (2012) Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the spanish neuro-oncology research group (GEINO). Anti Cancer Drugs 23: 659-665. doi:10.1097/CAD.0b013e3283534d3e. PubMed: 22634799.
42. Desjardins A, Reardon DA, Coan A, Marcello J, Herndon JE 2nd, et al. (2012) Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer 118: 1302-1312. doi:10.1002/cncr.26381. PubMed: 21792866.
43. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, et al. (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27: 4733-4740. doi:10.1200/JCO.2008.19.8721. PubMed: 19720927.
44. Tchaicha JH, Reyes SB, Shin J, Hossain MG, Lang FF, et al. (2011) Glioblastoma angiogenesis and tumor cell invasiveness are differentially regulated by beta8 integrin. Cancer Res 71: 6371-6381. doi:10.1158/0008-5472.CAN-11-0991. PubMed: 21859829.
45. Pope WB, Young JR, Ellingson BM, (2011) Advances in MRI assessment of gliomas and response to anti-VEGF therapy. Curr Neurol Neurosci Rep 11: 336-344. doi:10.1007/s11910-011-0179-x. PubMed: 21234719.
46. Gallego Perez-Larraya J, Lahutte M, Petrirena G, Reyes-Botero G, Gonzalez-Aguilar A, et al. (2012) Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: Comparative analysis of the macdonald, RECIST, RANO, and RECIST + F criteria. Neuro Oncol 14: 667-673.
47. Murray LJ, Bruno E, Uchida N, Hoffman R, Nayar R, et al. (1999) CD109 is expressed on a subpopulation of CD34+ cells enriched in hematopoietic stem and progenitor cells. Exp Hematol 27: 1282-1294. doi:10.1016/S0301-472X(99)00071-5. PubMed: 10428505.
48. Bizet AA, Liu K, Tran-Khanh N, Saksena A, Vorstenbosch J, et al. (2011) The TGF-beta co-receptor, CD109, promotes internalization and degradation of TGF-beta receptors. Biochim Biophys Acta 1813: 742-753. doi:10.1016/j.bbamcr.2011.01.028. PubMed: 21295082.
49. Maharaj AS, Walshe TE, Saint-Geniez M, Venkatesha S, Maldonado AE, et al. (2008) VEGF and TGF-beta are required for the maintenance of the choroid plexus and ependyma. J Exp Med 205: 491-501. doi:10.1084/jem.20072041. PubMed: 18268040.
50. Altman DG, McShane LM, Sauerbrei W, Taube SE, (2012) Reporting recommendations for tumor marker prognostic studies (REMARK): Explanation and elaboration. PLOS Med 9: e1001216. PubMed: 2264269122675273.
51. Lambrechts D, Lenz HJ, de Haas S, Carmeliet P, Scherer SJ, (2013) Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol 31: 1219-1230. doi:10.1200/JCO.2012.46.2762. PubMed: 23401453.